CAS: 1057249-41-8; 1-(3-Chlorophenyl)-3-(5-(2-(Thieno[3,2-D]Pyrimidin-4-Ylamino)Ethyl)Thiazol-2-yl)Urea

上下游产品

N-(4,4-Diethoxybutyl)Thieno[3,2-D]Pyrimidin-4-Amine 1187523-23-4

📜2-Bromo-4-(Thieno[3,2-D]Pyrimidin-4-Ylamino)Butanal Hydrobromide置于三乙胺体系中,用 乙醇,水,乙腈 用作溶剂,化学反应 10.8H,反应生成N-(3-氯苯基)-N'-[5-[2-(噻吩并[3,2-D]嘧啶-4-基氨基)乙基]-2-噻唑基]脲
参考文献: Aurora Kinase Inhibitors[fr] Inhibiteurs Des Aurora Kinases
标题: Aurora Kinase Inhibitors[fr] Inhibiteurs Des Aurora Kinases

专利信息

专利号:US-11285169-B2
优先权日:2013-03-13
标题 :Methods for modulating chemotherapeutic cytotoxicity
发明人：ROBERTS DAVID D; SOTO PANTOJA DAVID R
权利人:US HEALTH
摘要:Methods of reducing cytotoxicity of a chemotherapeutic agent to non-cancer cells by administering to a subject with cancer an effective amount of an agent that inhibits CD47 signaling and a DNA damaging agent, such as an anthracycline, topoisomerase inhibitor, or nucleotide synthesis inhibitor, are provided. Example disclosed methods reduce cardiotoxicity. In one example, the methods include administering to a subject with cancer an effective amount of a CD47 antisense morpholino oligonucleotide and an anthracycline such as doxorubicin. Methods of increasing cytotoxicity of a chemotherapeutic agent in cancer cells by administering to a subject with a tumor an effective amount of an agent that inhibits CD47 signaling and a DNA damaging agent such as an anthracycline, topoisomerase inhibitor, or nucleotide synthesis inhibitor, are also provided. In some embodiments, the inhibitor of CD47 signaling is administered to the subject before, during, or after the administration of the DNA damaging agent.

专利号:CN-102532052-B
优先权日:2010-06-24
标 题 :A class of thiazole amine compounds and their synthesis